Scleroderma Diagnostics and Therapeutics Market by Disease Types (Systemic Scleroderma [Limited Scleroderma and Diffused Scleroderma] and Localized Scleroderma [Linear Scleroderma and Morphea]), Test Types (Antibodies Test [Anti-U3, Anti-SCL70, and Anticentromere Antibodies], Urinalysis, Thyroid Function, Metabolic Panel, Muscle Enzymes, and Complete Blood Count), Drug Types (Alpha Blockers, Calcium Channel Blockers, Serotonin Receptor Antagonists, Local Nitrates, Angiotensin II Receptor Inhibitors, Statins, and Others [Antibiotics, Azathioprine, Prostanoids, Tetracycline, Prokinetics, and Cyclophosphamide]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

The global scleroderma diagnostics and therapeutics market size is projected to register a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the rising incidence of scleroderma cases and the increasing prevalence of genetic mutations along with the occurrence of extreme changes in the environment.

An autoimmune disease that affects the skin, muscles, blood vessels, and internal organs is known as scleroderma. The skin and connective tissues start to tighten & harden when a person is affected with such disorder. It is caused due to an immune response that is abnormal. Scleroderma occurs when collagen is overproduced in an individual’s body; however, the actual reason for the occurrence of scleroderma is not known. Scleroderma is a long-term and rare disease that affects women more than men. It mostly occurs between the ages of 30 to 50. The occurrence of scleroderma is likely four times more in women than in men.  Currently, no drug is available and approved for the treatment of scleroderma.

Approximately 2.5 million individuals are affected with scleroderma globally, which makes it a chronic disease. The report by Scleroderma & Raynaud’s UK stated that in 2018 about 19,000 individuals were diagnosed with scleroderma in the UK. The organization has been focusing on offering charity and continuously working for the betterment of those individuals who are suffering from scleroderma. As per the internal reports from Britain and Japan, the occurrence of scleroderma in adults is approximately 35 in 1 million.

Market Trends, Drivers, Restraints, and Opportunities                                                                

• Increasing levels of awareness among patients regarding healthcare coupled with the growing disposable income of the population are anticipated to fuel the market growth during the forecast period.
• Presence of medical needs and presence of highly unmet patients along with the introduction of new products are expected to propel the market growth during the forecast period.
• Growing focus of several pharmaceutical companies in order to develop novel drugs is anticipated to drive the market expansion in the coming years.
• Issues related to reimbursement policy and stringent regulatory policies are key challenges that can restrain the market growth during the forecast period.
• Ongoing research & development programs and expansion of clinical experiments in the field of scleroderma diagnostics & therapeutics are projected to create lucrative opportunities for market growth.

 Scope of the Report

The report on the global scleroderma diagnostics and therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights     

Systemic scleroderma segment is projected to account for a key market share  

On the basis of disease types, the global scleroderma diagnostics and therapeutics market is bifurcated into systemic scleroderma and localized scleroderma. The systemic scleroderma segment is further divided into limited scleroderma and diffused scleroderma while the localized scleroderma segment is sub-divided into linear scleroderma and morphea. The systemic scleroderma segment is projected to account for a key market share during the projected period owing to wide prevalence of the disease type and wide demand for advanced therapy for the disease treatment.

Antibodies segment is anticipated to exhibit a high CAGR

Based on test types, the market is segmented into antibodies test, urinalysis, thyroid function, metabolic panel, muscle enzymes, and complete blood count. The antibodies segment is further divided into anti-U3, anti-SCL70, and anticentromere antibodies. The antibodies segment is anticipated to exhibit a high CAGR during the forecast period owing to easy availability of the test type and most common form of type for the diagnostic of the disease.

Calcium channel blockers segment is expected to expand at a robust growth rate

On the basis of drug types, the global scleroderma diagnostics and therapeutics market is categorized as alpha blockers, calcium channel blockers, serotonin receptor antagonists, local nitrates, angiotensin II receptor inhibitors, statins, and others. The others segment is further divided into antibiotics, azathioprine, prostanoids, tetracycline, prokinetics, and cyclophosphamide. The calcium channel blockers segment is expected to expand at a robust growth rate during the forecast period owing to wide demand for the drug types.

Asia Pacific is anticipated to expand at a rapid pace

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to hold a major share of the market in the coming years attributed to high funding by governments and the presence of favorable regulations for the development of the therapy in the region. The development of new products along with the ongoing trials on a large scale to enhance efficiency is expected to further boost the regional market growth. However, the market of Asia Pacific is anticipated to expand at a rapid pace owing to the presence of unmet patient needs and high prevalence of the disorder in the region.

Segments

The global scleroderma diagnostics and therapeutics market has been segmented on the basis of

Disease Types

• Systemic Scleroderma
  • Limited Scleroderma
  • Diffused Scleroderma
• Localized Scleroderma
  • Linear Scleroderma
  • Morphea

Test Types

• Antibodies Test
  • Anti-U3
  • Anti-SCL70
  • Anticentromere Antibodies
• Urinalysis
• Thyroid Function
• Metabolic Panel
• Muscle Enzymes
• Complete Blood Count

Drug Types

• Alpha Blockers
• Calcium Channel Blockers
• Serotonin Receptor Antagonists
• Local Nitrates
• Angiotensin II Receptor Inhibitors
• Statins
• Others
  • Antibiotics
  • Azathiprine
  • Prostanoids
  • Tetracycline
  • Prokinetics
  • Cyclophosphamide

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• GlaxoSmithKline PLC
• Angion Biomedica Corp.
• BioLineRx, Ltd.
• Allergan, Inc.
• Bayer AG
• Corbus pharmaceuticals, Inc.
• Bristol-Myers Squibb Co.
• Digna Biotech
• F. Hoffmann-La Roche Ltd.
• Dynavax Technologies Corp.
• Daval International Ltd.;
• Active Biotech AB;
• Fibrocell Science, Inc.
• MedImmune
• LLCVida Therapeutics Inc.
• NovaLead Pharma Pvt. Ltd.
• iBio, Inc.
• VivaCell Biotechnology Espana S.L.

Competitive Landscape

Key players competing in the global scleroderma diagnostics and therapeutics market are GlaxoSmithKline PLC; Angion Biomedica Corp.; BioLineRx, Ltd.; Allergan, Inc.; Bayer AG; Corbus pharmaceuticals, Inc.; Bristol-Myers Squibb Co.; Digna Biotech; F. Hoffmann-La Roche Ltd.; Dynavax Technologies Corp.; Daval International Ltd.; Active Biotech AB; Fibrocell Science, Inc.; MedImmune; LLCVida Therapeutics Inc.; NovaLead Pharma Pvt. Ltd.; iBio, Inc.; and VivaCell Biotechnology Espana S.L. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion to increase their consumer base and expand their market position globally.